The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma
Abstract
To assess whether the progression of plasma cell tumors is accompanied by angiogenesis and secretion of matrix-degrading enzymes, bone marrow biopsy specimens from 20 patients with monoclonal gammopathy of undetermined significance (MGUS), 18 patients with nonactive multiple myeloma (MM), and 26 patients with active MM were evaluated for their angiogenic potential and matrix-metalloproteinase (MMP) production. A fivefold increase of the factor VIII+microvessel area was measured by a planimetric method of point counting in the bone marrow of patients with active MM as compared with nonactive MM and MGUS patients (P < .01). When serum-free conditioned media (CM) of plasma cells isolated from the bone marrow of each patient were tested in vivo for their angiogenic activity in the chick embryo chorioallantoic membrane (CAM) assay, the incidence of angiogenic samples was significantly higher (P< .01) in the active MM group (76%) compared with nonactive MM (33%) and MGUS (20%) groups. Moreover, a linear correlation (P < .01) was found between the extent of vascularization of the bone marrow of a given patient and the angiogenic activity exerted in the CAM assay by the plasma cells isolated from the same bone marrow. In vitro, a significantly higher fraction of the plasma cell CM samples from the active MM group stimulated human umbilical vein endothelial cell (HUVEC) proliferation (53%, P < .01), migration (42%, P < .05), and/or monocyte chemotaxis (38%,P < .05) when compared with nonactive MM and MGUS groups (ranging between 5% and 15% of the samples). Also, immunoassay of plasma cell extracts showed significantly higher (P < .01) levels of the angiogenic basic fibroblast growth factor (FGF)-2 in the active MM patients than in nonactive MM and MGUS patients (153 ± 59, 23 ± 17, and 31 ± 18 pg FGF-2/100 μg of protein, respectively). Accordingly, neutralizing anti–FGF-2 antibody caused a significant inhibition (ranging from 54% to 68%) of the biological activity exerted on cultured endothelial cells and in the CAM assay by plasma cell CM samples from active MM patients. Finally, in situ hybridization of bone marrow plasma cells and gelatin-zymography of their CM showed that active MM patients express significantly higher (P < .01) levels of MMP-2 mRNA and protein when compared with nonactive MM and MGUS patients, whereas MMP-9 expression was similar in all groups. Taken together, these findings indicate that the progression of plasma cell tumors is accompanied by an increase of bone marrow neovascularization. This is paralleled by an increased angiogenic and invasive potential of bone marrow plasma cells, which is dependent, at least in part, by FGF-2 and MMP-2 production. Induction of angiogenesis and secretion of MMPs by plasma cells in active disease may play a role in their medullary and extramedullary dissemination, raising the hypothesis that angiostatic/anti-MMP agents may be used for therapy of MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
A rapid in vitro assay for quantitating the invasive potential of tumor cells.
Albini, A., Iwamoto, Y., Hk, K., Gr, M., Aaronson, S. A., Jm, K., & McEwan, R. N. (1987) · PubMed · Cited by 1,778
Self-citationVan Wart, H. E., & Birkedal-Hansen, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5578 · Cited by 1,475
Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., & Comoglio, P. M. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.629 · Cited by 1,337
Self-citationBiology and biochemistry of proteinases in tumor invasion
Mignatti, P., & Rifkin, D. B. (1993) · Physiological Reviews · doi:10.1152/physrev.1993.73.1.161 · Cited by 1,244
Pepper, M. S., Ferrara, N., Orci, L., & Montesano, R. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)92277-5 · Cited by 858
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M., Leif Bergsagel, P., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 752
Quantification of cells cultured on 96-well plates
Kueng, W., Silber, E., & Eppenberger, U. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90710-0 · Cited by 634
Bone marrow angiogenesis and progression in multiple myeloma
Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., & Dammacco, F. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb08304.x · Cited by 630
Self-citationSpectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.
Pérez‐Atayde, A. R., Sallan, S. E., Tedrow, U. B., Connors, S. L., Allred, E. N., & Folkman, J. (1997) · Europe PMC (PubMed Central) · Cited by 553
Goto, F., Goto, K., Weindel, K., & Folkman, J. (1993) · PubMed · Cited by 459
Ray, J., & Stetler-Stevenson, W. (1994) · European Respiratory Journal · doi:10.1183/09031936.94.07112062 · Cited by 359
Vascular endothelial growth factor
Ferrara, N. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00387-5 · Cited by 355
Huhtala, P., Tuuttila, A., Chow, L. T., Lohi, J., Keski-Oja, J., & Tryggvason, K. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55326-6 · Cited by 333
Sieczkiewicz, G. J., Hussain, M., & Kohn, E. C. (2002) · Ovarian Cancer · doi:10.1007/978-1-4757-3587-1_17 · Cited by 295
Ellis, L. M., & Fidler, I. J. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00389-9 · Cited by 293
Yaccoby, S., Barlogie, B., & Epstein, J. (1998) · Blood · doi:10.1182/blood.v92.8.2908 · Cited by 255
New perspectives in clinical oncology from angiogenesis research
Folkman, J. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00423-6 · Cited by 250
Billadeau, D., Ahmann, G., Greipp, P., & Van Ness, B. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1023 · Cited by 231
Ribatti, D., Gualandris, A., Bastaki, M., Vacca, A., Iurlaro, M., Roncali, L., & Presta, M. (1997) · Journal of Vascular Research · doi:10.1159/000159256 · Cited by 218
Self-citationProduction of interleukin-1 by bone marrow myeloma cells
Cozzolino, F., Torcia, M., Aldinucci, D., Rubartelli, A., Miliani, A., Shaw, A., Lansdorp, P., & Di Guglielmo, R. (1989) · Blood · doi:10.1182/blood.v74.1.380.380 · Cited by 185
Barillé, S., Akhoundi, C., Collette, M., Mellerin, M.-P., Rapp, M.-J., Harousseau, J.-L., Bataille, R., & Amiot, M. (1997) · Blood · doi:10.1182/blood.v90.4.1649 · Cited by 183
Vassalli, J.-D., & Pepper, M. S. (1994) · Nature · doi:10.1038/370014a0 · Cited by 174
Ribatti, D., Vacca, A., Nico, B., Fanelli, M., Roncali, L., & Dammacco, F. (1996) · European Journal of Haematology · doi:10.1111/j.1600-0609.1996.tb00293.x · Cited by 172
Self-citationA Guide to Practical Stereology
Williams, M. A. (1984) · Europe PMC (PubMed Central) · Cited by 164
Production of cytokines by bone marrow cells obtained from patients with multiple myeloma
Lichtenstein, A. K., Berenson, J., Norman, D., Chang, M., & Carlile, A. (1989) · Blood · doi:10.1182/blood.v74.4.1266.1266 · Cited by 149
Characterization of adhesion molecules on human myeloma cell lines
Uchiyama, H., Barut, B., Chauhan, D., Cannistra, S., & Anderson, K. C. (1992) · Blood · doi:10.1182/blood.v80.9.2306.2306 · Cited by 146
Vacca, A., Loreto, M. D., Ribatti, D., Stefano, R. D., Gadaleta‐Caldarola, G., Iodice, G., Caloro, D., & Dammacco, F. (1995) · American Journal of Hematology · doi:10.1002/ajh.2830500103 · Cited by 131
Self-citationGualandris, A., Rusnati, M., Bastaki, M., Ziche, M., & Presta, M. (1998) · Springer eBooks · doi:10.1007/978-1-4899-0133-0_30 · Cited by 109
Self-citationBussolino, F., Arese, M., Montrucchio, G., Barra, L., Primo, L., Benelli, R., Sanavio, F., Aglietta, M., Ghigo, D., & Rola‐Pleszczynski, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118142 · Cited by 101
Self-citationCytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma.
Klein, B. (1995) · PubMed · Cited by 95
Watanabe, M., McCormick, K. L., Völker, K., Ortaldo, J. R., Wigginton, J. M., Brunda, M. J., Wiltrout, R. H., & Fogler, W. E. (1997) · Europe PMC (PubMed Central) · Cited by 62
Gualandris, A., Urbinati, C., Rusnati, M., Ziche, M., & Presta, M. (1994) · Journal of Cellular Physiology · doi:10.1002/jcp.1041610118 · Cited by 62
Self-citationProteolytic activity of human non-Hodgkin's lymphomas.
Ae, K., Hinek, A., Edwards, D. R., Lim, M. S., Cl, Z., Dr, B., Prusinkiewicz, C., Al, S., Ls, U., & Urbanski, S. (1998) · PubMed · Cited by 49
Role of Matrix, Fibroblasts and Type IV Collagenases in Tumor Progression and Invasion
Noël, A., Emonard, H., Polette, M., Birembaut, P., & Foidart, J. M. (1994) · Pathology - Research and Practice · doi:10.1016/s0344-0338(11)80999-4 · Cited by 42
Olivo, M., Bhardwaj, R. S., Schulze‐Osthoff, K., Sorg, C., Jacob, H. J., & Flamme, I. (1992) · The Anatomical Record · doi:10.1002/ar.1092340112 · Cited by 36
Cited by
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Metadata
- Authors
- Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F., & Dammacco, F.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-05-01
- Volume
- 93
- Issue
- 9
- Pages
- 3064-3073
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2159679541
- Cited by
- 599
- References
- 37
- FWCI
- 27.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.